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Abstract 
Retinal vein occlusion as a vasooclusive disorder of the retinal vein is the most common visually disabling 
disease affecting the retina after diabetic retinopathy, and is a frequent cause of vision loss and even 
blindness. Although it is more common in the middle-aged and elderly population, no age group is immune 
to it. The retinal vein occlusion pathogenesis has varied systemic and local implications that make it 
difficult to elaborate treatment guidelines. The disease entity has long been known, but there is a great deal 
of confusion regarding its management. Various new therapeutic approaches have been developed in the 
past few years. The objective of this review is to evaluate the treatments by steroids, emphasizing 
evidence-based ones, in the light of our current scientific knowledge of retinal vein occlusion.      
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1. Introduction 
Retinal vein occlusion as a vasooclusive disorder of the retinal vein is the most common visually disabling 
disease affecting the retina after diabetic retinopathy, and is a frequent cause of vision loss and even 
blindness (Shahid et al., 2006). 
Although it is more common in the middle-aged and elderly population, no age group is immune to it 
(Hayreh et al., 1994). 
In spite of the fact that the clinical entity of RVO has been known since 1878 (Michel, 1878) its 
management still remains highly controversial. The pathogenesis of RVO is multifactorial with both local 
factors and systemic diseases being etiologically important. 
Many case-control studies have examined the clinical features and risk factors in this disorder (The Eye 
Disease Case-Control Study, 1996; Lang and Spraul, 1997; Sperduto et al., 1998; Shahsuvaryan and 
Melkonyan, 2003; Koizumi et al, 2007). 
Known risk factors for RVO include systemic vascular disease, hypertension, diabetes mellitus, 
hyperlipidemia and glaucoma. Hypercoagulable states are associated with RVO.  
Depending on the location of the obstruction, the RVOs can be divided into central retinal vein occlusion 
(CRVO) and branch retinal vein occlusion (BRVO). 
In CRVO the obstruction is located in the central vein, at the level of the optic nerve, so most of the retina 
is affected. Anatomic features make the central retinal vein vulnerable to occlusion at this location. As the 
optic nerve and the accompanying central retinal artery and vein pass through the sieve-like connective 
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tissue of the lamina cribrosa, the central retinal vein normally narrows, and the dense connective tissue of 
the lamina cribrosa limits any expansion of the traversing optic nerve and vessels within. Any thickening of 
the central retinal artery, which shares a common fibrous tissue sheath with the vein, might easily compress 
the lumen of the adjacent central retinal vein and start in motion the sequence of events that lead to 
thrombus formation (Arakawa et al., 2011). 
In BRVO, the obstruction is located in one of the branches of the central vein, affecting only part of the 
posterior pole and the portion of the peripheral retina drained by occluded branch (Rehak and Rehak, 
2008). 
There are still gaps in understanding the aetiology and pathogenesis of circulatory disorders of the central 
retinal vein and its branches. 
Although various new therapeutic approaches have been developed in the past few years, existing therapy 
forms are subject to controversy and available data to same extent inconsistent. 
Over the years, many treatments have been advocated enthusiastically and success has been claimed. 
Except for a few prospective studies, all the reports are based on retrospective collection of information or 
on limited personal experience. Most of the reported studies have a variety of limitations, which make it 
hard to evaluate the claimed benefits. 
The objective of this review is to evaluate the treatments by steroids, emphasizing evidence-based ones, in 
the light of our current scientific knowledge of retinal vein occlusion. 
 
Glucocorticosteroids 
Glucocorticosteroids have multiple specific and non-specific effects. They are used in particular for their 
anti-inflammatory, anti-edemic, anti-proliferative and anti-angiogenic properties. In ophthalmology, 
steroids are administered topically, as periocular injections, or systemically. However, the problem with 
topical ocular application of drugs is that it does not allow for sufficient delivery to the posterior segment of 
the eye while long-term systemic administration of steroids is often associated with serious side effects. 
Given that the eye constitutes only 0.01% of body volume, that its sclerotic membrane makes it a relatively 
self-containing organ and that a substance works best when directly administered to the target area, 
intravitreous local administration by injection recommends itself as a means of high dosage local 
corticosteroid treatment. 
2. Triamcinolone Acetonide 
Triamcinolone acetonide is a crystalline, synthetic glucocorticoid with potency approximately five times 
that of cortisol. Since soluble triamcinolone is washed out of the eye within 24 hours of intravitreous 
injection, the crystalline form is preferable. 
2.1 Intravitrealinjection of triamcinolone acetonide 
Recent studies have reported successful treatment of macular edema secondary to CRVO and BRVO with 
intravitreal injection of triamcinolone acetonide. In patients with non-ischaemic CRVO and macular edema, 
improvement of macular edema and VA was reported .Meanwhile, Cekic et al. (2005), Ozdek et al. 
(2005) ,Gelston et al. (2006) and Jonas et al. (2006) stated that patients with non-ischaemic CRVO may 
respond more favourable than patients with ischaemic CRVO, and re-treatment may be necessary in some 
patients. The general consensus, however, is that improvement is not permanent and usually persists for a 
maximum of 3-6 months following one intravitreal injection (Ladjimi et al., 2005;Jonas ,2005;2006; Goff et 
al.,2006; Gunnlaugsdottir et al., 2006;Moschos et al.,, 2007; Oh et al., 2007). 
Gregori et al. (2006)  in a retrospective review of 40 eyes with CRVO (not differentiated into ischaemic 
and nonischaemic types) treated with IVTA claimed that some patients demonstrated visual improvement 
after injection and this improvement was maintained over one year with re-injections of TA. However, most 
patients did not have such favourable course. They stated that it is difficult to make any generalized 
prediction on how an individual patient will respond to IVTA even if the edema resolves, since it depends 
on the degree of macular ischaemia, the amount of retinal haemorrhage and the extent of irreversible 
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photoreceptor damage, and also an initial positive response could be lost with future treatments if the 
ischaemia progresses. 
Some authors have advocated the use of intravitreal triamcinolone acetonide in patients with macular 
edema due to BRVO, claiming significant improvement in VA (Cekic et al., 2005; Krepler et al., 2005;, 
Chen et al., 2006, Jonas,2005,2006;Ozkiris et al., 2006), however, the significant effect was not permanent 
and persisted for only one month. Oh et al. (2007) found that intravitreal triamcinolone is more effective in 
patients with BRVO who are treated earlier – after onset of or<or=3 months. In addition, optical coherence 
tomography (OCT) has demonstrated significant anatomic improvement in the majority of patients with 
macular edema due to CRVO (Degenring et al.,2003;Ip et al., 2003; Moschos et al., 2007)  and BRVO 
(Cekic et al., 2005;Krepler et al., 2005; Chen et al.,2006; Oh et al., 2007). Although systemically safe, 
intravitreal steroids have significant ocular side effects. 
Among the side effects mentioned are development of ocular hypertension (requiring antiglaucoma therapy 
including surgery) in about 50% of eyes after about 1-2 months ( Park et al., 2003;Cekic et al., 2005; Jonas, 
2005;2006;Goff et al., 2006), progression of cataract in some  (Jonas, 2005;2006)  and rarely 
endophthalmitis. In the elderly population of patients with RVO, intravitreal injection of TA leads to 
clinically significant posterior subcapsular cataract and nuclear cataract in about 15 to 20 % of eyes within 
one year of the intravitreal injection (Jonas, 2005; 2006).  Repeated intravitreal injection of TA could also 
result in primary open-angle glaucoma, particularly since, in patients with RVO there is already high 
incidence of glaucoma and ocular hypertension (Jonas, 2005; 2006).  Gregori et al. (2006) have found that 
patients with pre-existing open angle glaucoma had an IOP elevation at a higher rate than eyes without 
glaucoma, suggesting that this population may be at a higher risk for glaucoma surgery after intravitreal TA 
treatment. The authors stated that this potential risks need to be seriously considered and discussed with the 
patient given the transient and modest visual benefit of steroids. 
Jonas reported that, after intravitreal injection, triamcinolone acetonide can be detected in the aqueous 
humour for up to 1.5 years (2004) with earlier findings (2002) indicating up to 6 months. That may be 
responsible for the reported high incidence of markedly elevated intraocular pressure following intravitreal 
TA, as well regression of iris neovascularization (2001).  Dosages of TA used for intravitreal injection 
range from 4 to 20 mg. Thus far, there are no stadies on the optimal dose under various conditions. 
Moreover, the intravitreal method of delivery poses injection-related risks (Jager et al., 2004) of vitreous 
haemorrhage, retinal detachment and infections such as endophthalmitis with a rate of about 1:1000 (Jonas, 
2005;2006)  and also conjunctival necrosis (Srinivasan and Prasad ,2005)and macular hole (Lattanzio et 
al., 2007).  Recently more prevalent are non-infectious endophthalmitis and pseudoendophthalmitis with 
TA crystals appearing in the anterior chamber (Jonas et al., 2006). 
The SCORE ( Standard care vs. Corticosteroid for Retinal vein occlusion ) study, sponsored by the National 
Eye Institute (NEI) consists of 2 multicentere randomized, controlled clinical trials comparing the safety 
and efficacy of standard care with IVTA in either a 1- or 4-mg dose for vision loss  associated with 
macular edema secondary to CRVO or BRVO. In the CRVO trial, standard care therapy is observation. 
Retreatments are considered for persistent or new macular edema at 4-month intervals. 
The SCORE-CRVO study showed that both triamcinolone groups were superior to observation with respect 
to VA. The visual benefit of IVTA was demonstrated as early as 4 months and continued to 24 months; 
although there was less power at this point, the benefit appears to persist. However, in all 3 groups (1mg 
IVTA, 4mg IVTA or observation, there was a reduction of central retinal thickness from baseline to 24 
months. Therefore, the visual benefit of IVTA may be due not only to macular edema decrease, but also to 
other effects, such as anti-inflammatory or neuroprotective effects. The study report 5 also evidenced the 
superior safety profile of the 1-mg dose compared with the 4-mg dose, particularly with respect to 
glaucoma and cataract, rendering in the preferred dose in CRVO. 
In SCORE-BRVO IVTA injections was not found to be associated with improved VA outcomes compared 
with grid photocoagulation, being the standard care. The rates of adverse events were highest in the 4mg 
triamcinolone group.  The rates of adverse events in the 1 mg TA group were similar, with respect to 
surgical intervention for cataract and glaucoma, to the laser group, but laser treatment excluded any 
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possibility of injection-related adverse events. The SCORE Study Investigative Group concluded that grid 
photocoagulation should remain the benchmark against which other treatments are compared in clinical 
trials for eyes with vision loss associated with macular edema secondary to BRVO. 
2.2 Posterior sub-Tenon injection of triamcinolone acetonide 
Some authors (Iwao et al., 2007; Lin et al., 2007) have recently advocated the posterior sub-Tenon (PST) 
injection of 40 mg TA under topic anesthesia, based on claims that IOP elevation may be less common after 
PST injection than after intravitreal injection, however Iwao et al. (2007) have found that PST TA injection 
is associated with high rates of steroid-induced IOP elevation in eyes with previously normal IOP. 
Lin et al. (2007) in a prospective study of 18 eyes with CRVO treated by three biweekly PST TA injections, 
claimed that this treatment is effective in reversing cystoid macular edema (CME) and improving VA in 
recent-onset CRVO in the first 9 months before longstanding macular edema results in irreversible 
photoreceptor damage. No cataract progression or other complications were observed. They stated that 
patients with nonischaemic CRVO may respond more favourably than patients with ischaemic CRVO and 
further study with longer follow-up period is necessary. 
Recently Mizumo et al. (2007) in the experimental study have found that the periocular injection of TA 
effectively decreased retinal thickness and inhibited leukocyte-endothelium interactions in the retina after 
ischemia. Down regulation of adhesion molecules of retinal vascular endothelium induced by TA may play 
a role in the course.  
3. Dexamethasone  
The Ozurdex ( Allergan Inc., Irvine, CA, USA)  dexamethasone drug delivery system (DDS) was recently 
developed and approved by the FDA as a biodegradable intravitreal implant to provide sustained delivery of 
0.7 mg dexamethasone for the treatment of macular edema associated with RVO (Haller et al., 2010; 
London et al., 2011). 
Haller et al. (2010) concluded that for patients who have relatively short duration of macular edema, 
Ozurdex should be considered a viable treatment option. Increases in IOP were generally transient and 
similar following each treatment. Cataract adverse events occurred in 26% of patients treated with two 
injections and in 5% of patients who received no treatment over the 12-month study. 
3.1 Dexamethasone in complex therapy 
Taken into account that pathogenesis of CRVO is multifactorial with both local factors and systemic 
diseases being etiologically important we used the combination of different drugs named the therapeutic 
complex (Shahsuvaryan, 2004) in treatment of CRVO. Each of used drugs influences the specific link in the 
chain of pathologic changes resulted in RVO. The treatment included mix of Heparin and Dexamethason 
followed by Emoxypin and Dexamethason local in peribulbar injections, and Doxium, Solcoseryl, Diamox , 
Troxerutin, Vitamin E systemic during 15 days. The treatment is directed towards normalization the 
rheologic factors, resorbtion of blood clot in occluded vein, restoration of blood circulation, reducing 
vascular hyperpermeability and macular edema, activating of retinal oxygen metabolism and decreasing 
ischemic processes to prevent neovascularization. In CRVO patients with systemic hypertension also were 
used vasodilating drug to control blood pressure. To evaluate the efficacy of the therapeutic complex 
treatment we conducted a case-control study. A group of 20 patients treated after 2 weeks of the onset of 
occlusion was compared with controls without treatment after 1 month of the onset of occlusion. The 
groups were comparable for age, sex, systemic diseases (mainly presented systemic hypertension, less 
diabetes mellitus, myocardial infarction, atherosclerotic vascular disease). A statistically significant 
improvement in visual acuity was found in treated patients compared with control (t=2.66, p<0.01). 
Results of this study revealed that the complex medical therapy in RVO may be more effective than 
ordinary treatment or spontaneous regression and suggest that a randomized double-masked study should 
be conducted. 
The latest findings of Mataftsi et al. (2012) revealed that intracameral preservative-free dexamethasone in 
infantile cataract surgery did not seem to cause an increased risk for glaucoma. 
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4. Conclusion 
In spite of enthusiastic claims of success for various therapies, the reality is that the currently available 
treatments are associated with visual improvement in only a subset of patients and the approach to 
treatment of RVO is not evidence-based yet. The benefits and risks of therapy should be weighted in all 
treatment decisions. There is a need for large well-designed prospective randomized controlled trials with a 
long-term follow-up of new type steroid taken in a non-invasive way. 
 
5. List of Abbreviations 
BRVO – branch retinal vein occlusion 
CRVO – central retinal vein occlusion 
CME – cystoid macular edema 
IOP – intraocular pressure 
IVTA – intravitreal triamcinolone acetonide 
OCT – optical coherence tomography 
PST – posterior sub-Tenon injection 
RVO – retinal vein occlusion 
TA – triamcinolone acetonide 
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